Key facts: J.P. Morgan upgrades AstraZeneca; partners on cancer drug
I'm PortAI, I can summarize articles.
J.P. Morgan upgraded AstraZeneca to 'overweight', citing its strong drug pipeline as key to success in the European pharmaceutical market by 2026.1AstraZeneca and HUTCHMED are partnering on savolitinib, now included in China's National Reimbursement Drug List for treating advanced non-small cell lung cancer, effective January 1, 2026.2AstraZeneca has expanded its partnership with Pillar Biosciences to improve access to liquid biopsy technology in China.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments